A small company thinking big for patients
- To disrupt, eradicate, uproot
Evolution has put the small intestine at the center of biology.
Our aim is to create positive change in the world
Evelo is a clinical-stage biotech with a vision to dramatically improve healthcare.
Our work aims to harness SINTAX to modulate the body’s immune system – resolving inflammation to treat diseases such as psoriasis, atopic dermatitis, asthma, food allergies, arthritis, and inflammatory bowel disease.
Our product candidates are pharmaceutical preparations of single strains of non-live microbes or microbial extracellular vesicles that are taken orally and are able to treat inflammation throughout the body. In pre-clinical and Phase 1b studies, we have observed our lead product candidate EDP1815 to be well tolerated and comparable to placebo.
Our focus is on treating all stages of inflammatory diseases. Our investigational medicines are in clinical trials for psoriasis, atopic dermatitis, COVID-19, and cancer. We are also advancing our next generation product candidates – extracellular vesicles (EVs).